Back
NYLI MacKay ESG Core Plus Bond ETF Vs. Halozyme Therapeutics Industry Stock Comparison
Sell
28
ESGB
NYLI MacKay ESG Core Plus Bond ETF
Last Price:
21.01
Seasonality Move:
1.08%
Sell
39
HALO
Halozyme Therapeutics
Last Price:
45.65
Seasonality Move:
17.03%
Sell
28
NYLI MacKay ESG Core Plus Bond ETF (ESGB)
is a Sell
Is NYLI MacKay ESG Core Plus Bond ETF a Buy, Sell or Hold?
- The current NYLI MacKay ESG Core Plus Bond ETF [ESGB] share price is $20.99. The Score for ESGB is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.
- ESGB is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO)
is a Sell
Is Halozyme Therapeutics a Buy, Sell or Hold?
- The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
ESGB Stock Price Chart
What is NYLI MacKay ESG Core Plus Bond ETF's stock price today?
-
The NYLI MacKay ESG Core Plus Bond ETF share price today is $20.99
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ESGB is experiencing buying pressure, which is a positive indicator for future bullish movement.
HALO Stock Price Chart
What is Halozyme Therapeutics's stock price today?
-
The Halozyme Therapeutics share price today is $45.65
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
ESGB Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.11 | Sell |
| Relative Strength Index (14 RSI): | 35.83 | Sell |
| Chaikin Money Flow: | 1499 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (21.03 - 21.29) | Sell |
| Bollinger Bands (100): | (21.02 - 21.64) | Sell |
HALO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 30.2 | Sell |
| Chaikin Money Flow: | -7140517 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (49.94 - 58.56) | Sell |
| Bollinger Bands (100): | (52.16 - 60.38) | Sell |
ESGB Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 21.04 | Sell |
| 20-day SMA: | 21.11 | Sell |
| 50-day SMA: | 21.42 | Sell |
| 200-day SMA: | 21.05 | Sell |
| 8-day EMA: | 21.03 | Sell |
| 20-day EMA: | 21.13 | Sell |
| 50-day EMA: | 21.27 | Sell |
| 200-day EMA: | 21.11 | Sell |
HALO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.53 | Sell |
| 20-day SMA: | 54.48 | Sell |
| 50-day SMA: | 56.18 | Sell |
| 200-day SMA: | 48.93 | Sell |
| 8-day EMA: | 55 | Sell |
| 20-day EMA: | 55.41 | Sell |
| 50-day EMA: | 55.64 | Sell |
| 200-day EMA: | 50.73 | Sell |
NYLI MacKay ESG Core Plus Bond ETF Earnings Growth & ESGB Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Halozyme Therapeutics Earnings Growth & HALO Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.
NYLI MacKay ESG Core Plus Bond ETF Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Halozyme Therapeutics Technical Analysis
| Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | Nov 11 | Nov 12 | Nov 13 | Nov 14 | Nov 15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 04 | 05 | 06 | 07 | 08 | 11 | 12 | 13 | 14 | 15 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||